[1] Agopian VG, Kaldas FM, Hong JC, et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg, 2012, 256: 624-633.
[2] Murata S, Mine T, Sugihara F, et al. Interventional treatment for unresectable hepatocellular carcinoma World J Gastroenterol, 2014, 20: 13453-13465.
[3] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 2013, 499: 97-101.
[4] 王家珑, 李绍白. 肝脏病学(第3版). 北京: 人民卫生出版社, 2013, 716.
[5] 李青, 史为涛, 王勤英. 200例原发性肝癌的临床特征分析. 中国医药指南, 2013, 11: 42-44.
[6] 季盛, 卓蕴慧. 221例乙型肝炎相关性肝癌患者的流行病学分析. 肝脏, 2012, 17: 865.
[7] Guerrieri F, Belloni L, Pediconi N, et al. Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis, 2013, 33: 147-156.
[8] Huang Y, Tong S, Tai AW, et al. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21.Gastroenterology, 2011, 141:1412-1421.
[9] Shin HJ, Park YH, Kim SU,et al. Hepatitis B virus X protein regulates hepatic glucose homeostasis via activation of inducible nitric oxide synthase. J Biol Chem, 2011, 286: 29872-29881.
[10] Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.Hepatology, 2013, 57:399-408.
[11] Tsuchishima M, George J, Shiroeda H, et al. Chronic ingestion of ethanol induces hepatocellular carcinoma in mice without additional hepatic insult. Dig Dis Sci, 2013, 58:1923-1933.
[12] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, 142:1264-1273.
[13] 肝细胞癌抗病毒治疗专家组. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识. 肿瘤, 2014, 34: 295-302.
[14] Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci, 2010, 55:2744-2755.
[15] 赵伟, 戴朝六. 甲胎蛋白与自噬在肝癌发生发展中的作用及其相互关系. 现代肿瘤医学, 2015, 23: 2536-2539.
[16] Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010, 138:493-502.
[17] Tamura Y, Igarashi M, Kawai H, et al. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci, 2010, 55: 3576-3583. |
